Table 1. Basic Characteristics of DIO mice treated with Hif-1a ASO and control ASO compared to untreated animals.

	Hif-1α ASO treated mice	Control ASO treated mice	Untreated mice
N	10	10	10
Age on Day 0	20.5±2.1 wks	20.5±2.1 wks	20.5±2.1 wks
Body weight on Day 0 (g)	44.6±2.1	43.3±1.6	44.3±1.6
Body weight on Day 56	43.0±1.5	46.5±0.9*	47.2±0.7‡
Average food intake (g/24 hr)	2.7±0.1	2.6±0.1	2.8±0.1
Activity
Days 49–56: traveling/5 min	12.6±1.4	10.7±1.0	11.4±1.5
standing/5 min	10.2±1.3	11.4±1.3	11.5±1.7
Liver weight (g)	2.13±0.19	1.46±0.10†	1.53±0.11*
Liver/body weight (%)	5.12±0.30	3.17±0.15‡	3.22±0.19‡
Heart weight (g)	0.15±0.004	0.15±0.004	0.16±0.006
Epididymal fat (g)	1.59±0.13	2.05±0.19	2.21±0.19*
Inguinal fat (g)	1.30±0.16	2.31±0.20‡	2.36±0.25†
Omental fat (g)	0.51±0.07	0.70±0.06	0.58±0.04*
Brown fat (g)	0.47±0.05	0.58±0.04	0.66±0.04†
Plasma FFA (mmol/l)	0.32±0.03	0.27±0.11	0.32±0.10
Plasma glycerol (mmol/l)	0.032±0.002	0.036±0.004	0.043±0.008
β-hydroxybutyrate (mmol/l)	0.122±0.014	0.175±0.031	0.150±0.017

^*, † and ‡ denote p<0.05, <0.01 and <0.001 respectively for the difference with mice treated with HIF-1α antisense oligonucleotides (ASO).